Ventilator-Associated Pneumonia (VAP): Clinical Strategies, Treatment Challenges and Economic Concerns
- *Corresponding Author:
- Huma Ali
Faculty of Pharmaceutical Sciences
Jinnah Sindh Medical University
E-mail: [email protected]
Received Date: April 14, 2017; Accepted Date: May 29, 2017; Published Date: June 08, 2017
Citation: Zubair S, Ali H, Zafar F, Beg AE, Sial AA, et al. (2017) Ventilator- Associated Pneumonia (VAP): Clinical Strategies, Treatment Challenges and Economic Concerns. J Bioequiv Availab 9:432-436. doi: 10.4172/jbb.1000338
Copyright: © 2017 Zubair S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The clinical and economic features of Ventilator-Associated Pneumonia (VAP) are quite unclear, with an extensive array of values and contradictory results. The real challenge in this connection is to present the real estimate of the clinical and associated economic consequences of VAP. In developing countries like Pakistan, it is important to formulate an optimal institutional antimicrobial policy that can be used as a guide for empirical/prophylactic and specific therapies of antibiotics in VAP with more rational approach to lessen the rates of mortality and morbidity, decline the length of treatment and hospitalization and the significant impact in prevention of development of multidrug resistant strains and cost reduction.